SaniMed Science Group is a global life science investment and commercialization firm focused on Biotech, MedTech, TechBio, and AI-enabled healthcare. We partner with early- and growth-stage companies with clear clinical and regulatory pathways, providing expertise in FDA/NMPA strategy, preclinical and clinical development, device engineering, and cross-border execution. Leveraging a global network of hospitals, CRO/CDMOs, and industry partners, we help accelerate product readiness, reduce development risk, and enable efficient global commercialization to deliver long-term healthcare impact.

INVESTMENT

Name: SaniMed Science Group
Address: 7505 Fannin Street, Houston, TX, 77054, US
Telephone: 1-832-875-1816

SaniMed Science Group invests in high-potential Biotech, MedTech, TechBio, and AI-enabled healthcare companies through an execution-driven, cross-border investment platform. We combine strategic capital with hands-on support across R&D acceleration, regulatory strategy (FDA/NMPA), engineering, clinical development, and global commercialization. Through our Bridge Fund, Syndicates, and Strategic Investments, SaniMed helps innovators reduce development risk, reach critical milestones efficiently, and scale globally—partnering with founders and institutions to bring transformative healthcare technologies to market. Read More

PROJECTS

TomoWave Medical Group

TomoWave Medical Group focuses on advancing 3D/4D Photoacoustic Tomography (PAT) technology for high-resolution structural, functional, and molecular imaging. Its systems enable real-time, image-guided preclinical research as well as non-invasive, image-guided biopsies and surgical procedures. As a leader in photoacoustic imaging equipment, TomoWave has launched both preclinical and clinical product lines. Its Preclinical Animal Photoacoustic Imaging System has achieved strong commercial traction, generating over USD 3.5 million in sales.

Torskal: Pioneering Green Nanomedicine for Cancer Therapy

Torskal is a French biotech company pioneering non-ionizing plasmonic photothermal therapy (PTT) for oncology. Its lead program, TSK-001, targets nodular basal-cell carcinoma (BCC) using eco-friendly, plant-derived gold nanoparticles activated by near-infrared light. This method destroys cancer cells non-invasively and precisely, offering a safer alternative to traditional therapies. Torskal stands out for its commitment to green nanotechnology, enhancing biocompatibility and sustainability. Led by Dr. Anne-Laure Morel, the company collaborates with top clinical and academic partners and is preparing for Phase 1–2 clinical trials to assess TSK-001’s safety and efficacy.